CagriSema
aka cagrisema
Mechanism
CagriSema is Novo Nordisk's investigational once-weekly fixed-dose co-formulation of cagrilintide 2.4 mg (long-acting amylin analog) with semaglutide 2.4 mg (GLP-1 receptor agonist) for chronic weight management. Unlike the other grey-market blends, it has a proper Phase 3 clinical program. Novo Nordisk filed an FDA NDA in December 2025; as of April 2026 it is under FDA review and not yet approved.
Identification
| Typical dose | 2.4 mg/week cagrilintide + 2.4 mg/week semaglutide, subcutaneous once-weekly; dose-escalation starting at 0.16 mg/week cagrilintide escalated over 16 weeks |
|---|---|
| Half-life | Cagrilintide ~184 hours (~7.7 days); semaglutide ~158 hours (~6.6 days) |
Vendors selling CagriSema
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Profound Aminos | 10 mg | $99.00 | — | 95 |
| Qihang Peptide | — | — | — | 87 |
| Simple Peptide | 10 mg | $178.00 | — | 85 |
| Mandy | 10 mg | $130.00 | — | 43 |
| MJT peptides | 10 mg | $173.00 | — | 39 |
| Apollo Peptide Sciences | — | — | — | — |
| Alpha Omega | 10 mg | $178.00 | — | — |
| Modern Research Peptides | 10 mg | $70.99 | — | — |
Research
Background Obesity is a global health challenge associated with substantial cardiometabolic morbidity. Cagrilintide, a long-acting amylin analogue, alone or in combination with semaglutide (CagriSema), has emerged as a novel pharmacologic strategy for weight management.
source →This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide.
source →Background Long-acting amylin-based therapies (ABTs) are emerging anti-obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and rank agents and doses within a network meta-analysis (NMA) framew…
source →Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.
source →Background Obesity is a complex chronic disease requiring effective long-term management. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity.
source →The obesity epidemic is a major health burden that enhances susceptibility to a broad spectrum of metabolic-associated comorbidities, ranging from fatty liver disease and endocrine dysfunction to traditional risks like type 2 diabetes mellitus and cardiovascular disease.
source →The pharmaceutical industry is currently engaged in an intense competition to maximize weight reduction percentages.
source →Background Basal insulin treatment for type 2 diabetes often results in inadequate glycaemic control and is associated with weight gain and increased risk of hypoglycaemia.
source →Objective To provide an up-to-date evidence summary about the comparative benefits and harms of drugs for adults with overweight or obesity to inform decision making for policymakers, payers, clinicians, and patients.
source →Background Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.
source →Background Fixed-dose combination of semaglutide/cagrilintide (CagriSema 2.4 mg/2.4 mg) has demonstrated significant and clinically relevant body weight reductions in adults with overweight or obesity compared with placebo.
source →Background The amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide have complementary effects on glycaemic control and bodyweight.
source →This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe.
source →This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants.
source →This research study tests if CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight. Participant will either get CagriSema (active medicine) or placebo (a dummy medicine), which has no effect on the body. The treatment participants get is decided by chance.
source →This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body.
source →This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body.
source →This study will compare the blood levels of cagrilintide and semaglutide when the same dose is given in two different versions of CagriSema. CagriSema is a medicine that combines two medicines called cagrilintide and semaglutide. It is still being tested in studies and is not yet available for doctors to prescribe.
source →The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone.
source →This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants get is decided by chance.
source →